Relationships between Hepatitis C Virus Replication and CXCL-8 Production In Vitro

Koo, Bon Chang A.; McPoland, Paula; Wagoner, Jessica; Kane, Olivia J.; Lohmann, Volker; Polyak, Stephen J.

doi:10.1128/jvi.00519-06

Cited by 34 publications

(32 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rates of annual decline in FEV1 and diffusing capacity for carbon monoxide in COPD patients were significantly higher in HCV-positive patients than in HCV-negative patients (25). These declines were also higher in HCV-positive asthmatic patients than in HCV-negative and interferon responding asthmatic patients (26 (27,28), and that the IL-8 levels are associated with HCV replication (29). The enhanced production of IL-8 is induced via transcriptional ac-T a b l e 3 .…”

Section: Smoking Is a Major Risk Factor For Copd And Aging Increases mentioning

confidence: 80%

Prevalence of COPD in Primary Care Clinics: Correlation with Non-Respiratory Diseases

et al. 2008

View full text Add to dashboard Cite

Background and Objective Various extrapulmonary effects and comorbidities have been noted to contribute to the burden of chronic obstructive pulmonary disease (COPD). However, the relationship between the prevalence of COPD and non-respiratory diseases has not been well investigated. The aim of the present study was to determine whether or not COPD is different among patients already suffering from other diseases.

show abstract

Section: Smoking Is a Major Risk Factor For Copd And Aging Increases mentioning

confidence: 80%

Prevalence of COPD in Primary Care Clinics: Correlation with Non-Respiratory Diseases

et al. 2008

View full text Add to dashboard Cite

show abstract

“…The most plausible molecule is interleukin (IL)-8, which is one of the key molecules in the pathogenesis of COPD. Hepatitis C virus infection induces IL-8 production in human endothelial cells (18,19), and the IL-8 levels are associated with HCV replication (20). The enhanced production of IL-8 is induced via transcriptional activation and mRNA stabilization (18).…”

Section: Discussionmentioning

confidence: 99%

High COPD Prevalence in Patients with Liver Disease

et al. 2010

View full text Add to dashboard Cite

Objective Comorbidities of chronic obstructive pulmonary disease (COPD) have been recognized as an important issue in COPD management. We have reported that patients with liver diseases show a higher prevalence of COPD, but the number of patients with liver diseases was small and the details of liver diseases were not clearly investigated. In this study, we investigated the prevalence of COPD in patients with liver diseases by recruiting a large number of patients, and also investigated was the effect of hepatitis virus infection on COPD prevalence. Patients and Methods Six hundred sixty-six patients were recruited from 9 primary care clinics and three hospitals. All of these patients were aged 40 years or older with chronic diseases and had not been diagnosed as having respiratory diseases. A spirometry was performed without administration of an inhaled bronchodilator. Airflow limitation was defined as FEV1/FVC <70%. Underlying diseases were diagnosed by doctors of the clinics or the hospitals. Results Two hundred fifty-six patients had liver diseases, and 410 did not. Of 410 patients without liver diseases, 37 patients (9.0%) were diagnosed as COPD, and of 256 patients with liver diseases, 35 patients (13.8%) were COPD. When the prevalence was analyzed according to smoking, age and gender, liver diseases showed a significantly high odds ratio (2.10, 95%CI 1.23-3.57, p=0.006), but hepatitis virus infection showed a non-significant tendency toward a high odds ratio. Conclusion The patients with liver diseases had a significantly high prevalence of COPD. The presence of liver disease might become a useful predictor for the early detection of COPD.

show abstract

“…Huh7.5.1 cells were grown in Huh7 medium as described (9). JFH-1 viral stock preparation, cell infection, and titration was performed as described (33)(34)(35). For antiviral assays, cells were in infected at a multiplicity of infection of 0.05 and protein and RNA harvested 72 h postinfection.…”

Section: Methodsmentioning

confidence: 99%

Identification of hepatoprotective flavonolignans from silymarin

Polyak

Morishima

Lohmann

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

285

217

View full text Add to dashboard Cite

Silymarin, also known as milk thistle extract, inhibits hepatitis C virus (HCV) infection and also displays antioxidant, anti-inflammatory, and immunomodulatory actions that contribute to its hepatoprotective effects. In the current study, we evaluated the hepatoprotective actions of the seven major flavonolignans and one flavonoid that comprise silymarin. Activities tested included inhibition of: HCV cell culture infection, NS5B polymerase activity, TNF-α-induced NF-κB transcription, virus-induced oxidative stress, and T-cell proliferation. All compounds were well tolerated by Huh7 human hepatoma cells up to 80 μM, except for isosilybin B, which was toxic to cells above 10 μM. Select compounds had stronger hepatoprotective functions than silymarin in all assays tested except in T cell proliferation. Pure compounds inhibited JFH-1 NS5B polymerase but only at concentrations above 300 μM. Silymarin suppressed TNF-α activation of NF-κB dependent transcription, which involved partial inhibition of IκB and RelA/p65 serine phosphorylation, and p50 and p65 nuclear translocation, without affecting binding of p50 and p65 to DNA. All compounds blocked JFH-1 virus-induced oxidative stress, including compounds that lacked antiviral activity. The most potent compounds across multiple assays were taxifolin, isosilybin A, silybin A, silybin B, and silibinin, a mixture of silybin A and silybin B. The data suggest that silymarin-and silymarin-derived compounds may influence HCV disease course in some patients. Studies where standardized silymarin is dosed to identify specific clinical endpoints are urgently needed.hepatitis C | liver disease | milk thistle | botanical medicine | hepatoprotection C hronic hepatitis C virus (HCV) is a major global medical problem. In the United States, millions of people are affected, the number of patients with HCV-induced end-stage liver disease is growing (1), and this condition is already the leading indication for liver transplantation (2). The current standard of care for chronic hepatitis C, pegylated IFN-α and ribavirin, results in sustained elimination of virus in 55% of treated patients (3, 4). However, significant numbers of patients do not clear the virus and are intolerant to, have contraindications to, or opt out of therapy. Furthermore, because emerging specifically targeted antiviral therapy for HCV therapies need to be administered with pegylated IFN plus ribavirin (5), it is likely that many patients will not tolerate this therapy. Thus, there are many patients who have no other Food and Drug Administration-approved options to eliminate HCV and prevent progression of liver disease. As a result, many individuals have opted for complementary and alternative medicine-based approaches, including botanicals, to treat their chronic hepatitis C. Indeed, as many as 13 to 23% of American patients with chronic liver disease use botanical medicines, with silymarin being the most popular (6, 7).Silymarin, an extract from the seeds of the milk thistle plant, Silybum marianum, has been used fo...

show abstract

Relationships between Hepatitis C Virus Replication and CXCL-8 Production In Vitro

Cited by 34 publications

References 48 publications

Prevalence of COPD in Primary Care Clinics: Correlation with Non-Respiratory Diseases

Prevalence of COPD in Primary Care Clinics: Correlation with Non-Respiratory Diseases

High COPD Prevalence in Patients with Liver Disease

Identification of hepatoprotective flavonolignans from silymarin

Contact Info

Product

Resources

About